Cytomegalovirus Retinitis During Idecabtagene Vicleucel Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Transplant Infectious Disease · 2025
DOI: 10.1111/tid.70040 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant Infectious Disease, 2025. Verfasst von Taku Kikuchi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan. Hauptthemen laut MEDLINE: Multiple Myeloma, Cytomegalovirus Retinitis, Immunotherapy, Adoptive, Antigens, CD19. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Abstract (Originalsprache)
Background
Chimeric antigen receptor T‐cell (CAR‐T) therapy has improved outcomes in patients with triple‐class‐exposed relapsed/refractory multiple myeloma (RRMM); however, it is associated with complications, including infections. Cytomegalovirus (CMV) infection is one of the infections associated with idecabtagene vicleucel (ide‐cel) treatment. While there have been several reports on CMV replication, CMV retinitis has only been documented in case reports, making it a severe but under‐reported complication. Study Design This retrospective single‐institution study was conducted at the Japanese Red Cross Medical Center. The study analyzed the clinical features of CMV retinitis in 53 patients with RRMM treated with ide‐cel between December 2022 and December 2024. CMV retinitis was diagnosed based on ophthalmological findings, with CMV polymerase chain reaction (PCR) confirmation in the vitreous fluid, if necessary.
Results
The cumulative incidence of CMV retinitis at 6 months was 9.2%, with a median onset time of 2.2 months postinfusion. Among the four patients with CMV retinitis, three patients experienced visual impairment and one patient was asymptomatic. One patient was diagnosed with CMV retinitis, despite having negative serum CMV PCR results, which highlights the limitations of replication‐based screening. All patients required treatment, with one patient achieving improvement and three patients undergoing ongoing treatments.
Conclusions
CMV retinitis is a significant complication of ide‐cel therapy. Regular CMV PCR is important, but early ophthalmological consultations are crucial for timely detection and management, even in the absence of CMV replication, particularly when visual impairment develops. Further studies are needed to identify the risk factors and establish preventive strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
- Department of Pharmacy, Japanese Red Cross Medical Center, Tokyo, Japan.
ORCID-Profile: Taku Kikuchi
Zitieren
APA
Kikuchi, T., Watanabe, M., Tsukada, N., Matsumoto, C., Nomura-Yogo, M., Kunisada, K., Sawada, H., Sato, K., Takei, T., Ogura, M., Abe, Y., Suzuki, K., Hosoya, O., & Ishida, T. (2025). Cytomegalovirus Retinitis During Idecabtagene Vicleucel Therapy in Patients With Relapsed/Refractory Multiple Myeloma. Transplant Infectious Disease. https://doi.org/10.1111/tid.70040
Vancouver
Kikuchi T, Watanabe M, Tsukada N, Matsumoto C, Nomura-Yogo M, Kunisada K, et al. Cytomegalovirus Retinitis During Idecabtagene Vicleucel Therapy in Patients With Relapsed/Refractory Multiple Myeloma. Transplant Infectious Disease. 2025. doi:10.1111/tid.70040
BibTeX
@article{Kikuchi2025,
author = {Kikuchi, Taku and Watanabe, Miyu and Tsukada, Nobuhiro and Matsumoto, Chiaki and Nomura-Yogo, Moe and Kunisada, Kodai and Sawada, Haruka and Sato, Kota and Takei, Tomomi and Ogura, Mizuki and Abe, Yu and Suzuki, Kenshi and Hosoya, Osamu and Ishida, Tadao},
title = {Cytomegalovirus Retinitis During Idecabtagene Vicleucel Therapy in Patients With Relapsed/Refractory Multiple Myeloma},
journal = {Transplant Infectious Disease},
year = {2025},
doi = {10.1111/tid.70040}
}
EUVIMED